BLA 761102 · Servier Pharma LLC
Asparlas
Calaspargase Pegol-Mknl · Intravenous · Asparagine-specific Enzyme
NovelOrphanLast checked: Nov 19, 2026Latest source record: Nov 29, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Dec 20, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
27
7 Phase 3, 9 recruiting
FAERS reports
804
736 serious, 65 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2024.
ASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. ( 1.1 ) 1.1 Acute Lymphoblastic Leukemia ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Mechanism: L-asparaginase is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of ASPARLAS is thought to be based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize asparagine, and therefore depend on an exogenous source of asparagine for survival.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ASPARLAS · CALASPARGASE PEGOL-MKNL 3750UNITS/5ML · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Calaspargase Pegol" as an intervention, any sponsor and status, largest first.
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
Children's Oncology GroupResearch network
NCT01225874 · 3,762 participants · Start Dec 1999 · Primary completion Mar 2006
Drug: SC-PEG E. coli L-asparaginase; cytarabine and 6 more · For: Leukemia
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaPivotal-lookingActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT03117751 · 790 participants · Start Mar 29, 2017 · Primary completion Sep 30, 2026
Drug: Prednisone; Vincristine and 21 more · For: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
Sites: Palo Alto, California; San Diego, California; Peoria, Illinois · 8 sites in all
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Pivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT04546399 · 461 participants (planned) · Start Dec 17, 2020 · Primary completion Jun 30, 2028
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 9 more · For: Down Syndrome; Recurrent B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 229 sites in all
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaPivotal-lookingActive, not recruiting
Children's Oncology GroupResearch network
NCT05602194 · 440 participants (planned) · Start Aug 24, 2023 · Primary completion Sep 30, 2026
Drug: Calaspargase Pegol; Pegaspargase · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 228 sites in all
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
Children's Oncology GroupResearch network
NCT03007147 · 352 participants · Start Aug 8, 2017 · Primary completion Jun 30, 2026
Drug: Calaspargase Pegol; Cyclophosphamide and 20 more · For: Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia; Mixed Phenotype Acute Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 226 sites in all
- SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic LymphomaPivotal-lookingActive, not recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT01574274 · 240 participants · Start Jun 2012 · Primary completion Jul 2021
Drug: SC-PEG; Oncaspar · For: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Sites: Boston, Massachusetts; New York, New York; Providence, Rhode Island · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypersensitivity211
- anaphylactic reaction103
- febrile neutropenia71
- pancreatitis71
- infusion related reaction67
- hypertriglyceridaemia56
- vomiting36
- tachycardia28
- neutropenia26
- pancytopenia25
- cough23
- hyperglycaemia23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 5 |
| 2023 | 187 |
| 2024 | 284 |
| 2025 | 158 |
| 2026 | 170 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM, Blonquist TM, Stevenson KE, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL, Schore RJ, Devidas M, et al. · J Clin Oncol 2014 · Multicenter Study, Randomized Controlled Trial
Sponsor: Servier Pharma LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.